ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is a Healthcare company (Biotechnology) with a market capitalization of $367M. The Maz Rating grades it against the other companies in its sector.
ARS Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.65, ARS Pharmaceuticals, Inc. trades at 3.0x sales. Over the last twelve months it generated about $123M of revenue and a net loss of $205M. It runs a gross margin of 73.4%, an operating margin of -161.5% and a net margin of -163.6%. It shows return on equity of -453.9%, return on invested capital of -105.7% and a free cash flow yield of -49.9%. On the balance sheet: a debt-to-equity ratio of -16.48 and a current ratio of 3.25. Over the past 52 weeks the share price ranged from $2.44 to $13.15, with a beta of 0.88.
ARS Pharmaceuticals, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 4 Buy and 6 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, ARS Pharmaceuticals, Inc. (SPRY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 44.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 31.3% / 30% · Interest income / Revenue 3.01% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 44.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 31.3% / 33% · Receivables / Mkt Cap (36m) 11.9% / 49% · Interest income / Revenue 3.01% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 44.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 31.3% / 33.33% · Receivables / Mkt Cap (24m) 11.9% / 33.33% · Interest income / Revenue 3.01% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 50.3% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 65.2% / 33.33% · Receivables / Avg Assets (4Q) 13.9% / 33.33% · Interest income / Revenue 3.01% / 5% | Fail |
| FTSE | Debt / Total Assets 78.3% / 33.33% · (Cash+ST Inv) / Total Assets 55.0% / 33.33% · (Cash+Recv) / Total Assets 76.0% / 33.33% · Interest income / Revenue 3.01% / 5% | Fail |
No. As of September 2026, ARS Pharmaceuticals, Inc. (SPRY) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. ARS Pharmaceuticals, Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
About 3.01% of each dividend: ARS Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.